Correlation Between Mineralys Therapeutics, and Connect Biopharma

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Connect Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Connect Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Connect Biopharma Holdings, you can compare the effects of market volatilities on Mineralys Therapeutics, and Connect Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Connect Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Connect Biopharma.

Diversification Opportunities for Mineralys Therapeutics, and Connect Biopharma

0.02

Correlation Coefficient

Mineralys Therapeutics,  Connect Biopharma

Significant diversification

The 3 months correlation between Mineralys and Connect is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Connect Biopharma Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Connect Biopharma and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Connect Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Connect Biopharma has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Connect Biopharma go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Connect Biopharma

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.78 times more return on investment than Connect Biopharma. However, Mineralys Therapeutics, Common is 1.29 times less risky than Connect Biopharma. It trades about 0.06 of its potential returns per unit of risk. Connect Biopharma Holdings is currently generating about -0.05 per unit of risk. If you would invest  1,195  in Mineralys Therapeutics, Common on August 31, 2024 and sell it today you would earn a total of  116.00  from holding Mineralys Therapeutics, Common or generate 9.71% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.44%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Connect Biopharma Holdings

Mineralys Therapeutics,

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Mineralys Therapeutics, unveiled solid returns over the last few months and may actually be approaching a breakup point.

Connect Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Connect Biopharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Mineralys Therapeutics, and Connect Biopharma

The main advantage of trading using opposite Mineralys Therapeutics, and Connect Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Connect Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Connect Biopharma will offset losses from the drop in Connect Biopharma's long position.

The idea behind Mineralys Therapeutics, Common and Connect Biopharma Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.